Proteins and Peptides

18 June 2015

BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study

17 June 2015

Synergy Pharmaceuticals Announces Positive Results in the First Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC)

15 June 2015

Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly

15 June 2015

Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients

10 June 2015

Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia

10 June 2015

Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine A

8 June 2015

Sanofi’s Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk

8 June 2015

AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101

8 June 2015

Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

8 June 2015

Intarcia Announces Presentations At ADA Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 — A GLP-1 RA For Type 2 Diabetes

8 June 2015

Hanmi Pharmaceutical: Efpeglenatide (GLP-1 Analog), the Promising Potential for Anti-Diabetes/Anti-Obesity Treatment as Once Weekly up to Once Monthly

8 June 2015

PhaseBio Pharmaceuticals Announces Positive Data for Type 2 Diabetes Treatments PE0139 and PB1023

8 June 2015

Hanmi Pharmaceutical : Once-Weekly Insulin Combination, ‘LAPSInsulin Combo’, Suggests a New Diabetes Therapeutic Option

8 June 2015

Lilly’s Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes

8 June 2015

Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes

8 June 2015

New Xultophy® (IDegLira) Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change and Lower Rate of Hypoglycaemia Versus Insulin Glargine

8 June 2015

Sanofi Announces Positive Results for Toujeo® in Phase III Study Extension in Japanese People with Uncontrolled Diabetes

8 June 2015

Presentations on two novel Zealand preclinical peptide therapeutics as possible approaches for the treatment of Type 2 diabetes and obesity at the American Diabetes Association’s (ADA) 74th Scientific Sessions

6 June 2015

Sanofi’s Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin

5 June 2015

Horizon Pharma plc Initiates Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich’s Ataxia

5 June 2015

Synageva BioPharma Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB

5 June 2015

Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Children with Brain Cancer

4 June 2015

FDA Grants Breakthrough Therapy Designation for Genzyme’s Olipudase Alfa

3 June 2015

Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate

2 June 2015

ERYTECH reported full GRASPA® Phase III results in ALL and provided update on AML Phase IIb at ASCO

1 June 2015

ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action

1 June 2015

Angiochem Presents ANG1005 Data on Breast Cancer Patients with Brain Metastasis at the 2015 American Society for Clinical Oncology Annual Meeting

1 June 2015

Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients

1 June 2015

PharmaMar completes patient recruitment of Phase III registration trial (ADMYRE) with APLIDIN® (plitidepsin) in multiple myeloma

31 May 2015

Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

DLL3-Targeted Immunotherapy Candidates Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies: a business, pipeline and competitor analysis from an industry perspective

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

CD73 Inhibitor Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics